Dr. Dickerson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-456-2382Fax+1 214-867-5696
Summary
- Dr. Kathryn Dickerson is a pediatric hematologist/oncologist in Dallas, TX and is affiliated with multiple hospitals in the area, including Children's Medical Center Dallas and University of Texas Southwestern Medical Center. She received her medical degree from Indiana University School of Medicine and has been in practice 6 years. She also speaks multiple languages, including Spanish. She is experienced in autoimmune hemolytic anemia, thalassemias, immune thrombocytopenic purpura, bone marrow failure syndromes, and fanconi anemia. She has more than 10 publications and over 500 citings.
Education & Training
- University of Texas Southwestern Medical SchoolMS, Clinical Sciences, Center for Translational Medicine Clinical Scholar, 2015 - 2018
- University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2014 - 2017
- Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 2011 - 2014
- Indiana University School of MedicineClass of 2011
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- TX State Medical License 2017 - 2026
- OH State Medical License 2011 - 2017
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Start of enrollment: 2016 Aug 01
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Start of enrollment: 2017 Sep 30
- Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome Start of enrollment: 2019 Oct 24
Publications & Presentations
PubMed
- T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.Giovanni A Botten, Yuannyu Zhang, Franklin Fuda, Prasad Koduru, Olga K Weinberg
British Journal of Haematology. 2024-08-01 - 10 citationsA phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.Raffaele Badolato, Laia Alsina, Antoine Azar, Yves Bertrand, Audrey A Bolyard
Blood. 2024-07-04 - Pancytopenia and haematopoietic precursor vacuolisation in an infant: Clues to Pearson syndrome.Jordan H Driskill, Miguel Dario Cantu, Jessica Garcia, Kathryn E Dickerson, Weina Chen
British Journal of Haematology. 2023-09-01
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: